Press Release
Article Category
![Amyotrophic lateral sclerosis (ALS)](https://parsianpharma.com/wp-content/uploads/2024/01/Amyotrophic-lateral-sclerosis-33.jpg)
Amyotrophic lateral sclerosis (ALS)
Review over Amyotrophic Lateral Sclerosis (ALS) and the First FDA-Approved Drug for Treatment of
![Molnupiravir](https://parsianpharma.com/wp-content/uploads/2024/01/micron-banner.jpg)
Molnupiravir
Molnupiravir may be effective against the omicron sub-variant BA.5 According to a study
![Monkeypox](https://parsianpharma.com/wp-content/uploads/2024/01/MONKEYPOX-01.jpg)
Monkeypox
The current monkeypox situation is consistently evolving and subject to change. The aim of
![](https://parsianpharma.com/wp-content/uploads/2024/01/inflammatory-.jpg)
Arthritis
World AUTO immune & AUTO inflammatory Arthritis Day This event historically unites thousands
![molnupiravir](https://parsianpharma.com/wp-content/uploads/2024/01/Molnupiravir-222.jpg)
WHO Backs Molnupiravir for High-Risk Covid-19 Patients
The ninth update of WHO’s guideline on COVID-19 therapeutics includes a conditional recommendation
![Amyotrophic Lateral Sclerosis](https://parsianpharma.com/wp-content/uploads/2024/01/Amyotrophic-Lateral-Sclerosis-.jpg)
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) Global Day Annually the International ALS/MND Associations celebrates 21 June
![Molnupiravir](https://parsianpharma.com/wp-content/uploads/2024/01/monloupiravi-parsian-pharma.jpg)
Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir
Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir U.S FDA advisory panel